Godavari Drugs Limited

BSE:530317 Stock Report

Market Cap: ₹860.7m

Godavari Drugs Past Earnings Performance

Past criteria checks 5/6

Godavari Drugs has been growing earnings at an average annual rate of 16.9%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 9.8% per year. Godavari Drugs's return on equity is 15.8%, and it has net margins of 4.7%.

Key information

16.9%

Earnings growth rate

16.9%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate9.8%
Return on equity15.8%
Net Margin4.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Godavari Drugs makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:530317 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,40466550
30 Jun 241,54464520
31 Mar 241,56755530
31 Dec 231,55842510
30 Sep 231,52137510
30 Jun 231,53337500
31 Mar 231,59638500
31 Dec 221,67037480
30 Sep 221,61444490
30 Jun 221,59547510
31 Mar 221,61352510
31 Dec 211,49653510
30 Sep 211,49149490
30 Jun 211,41447440
31 Mar 211,22841400
31 Dec 201,14436370
30 Sep 201,07231350
30 Jun 2099324340
31 Mar 2095820350
31 Dec 1996016360
30 Sep 1994715360
30 Jun 1989715360
31 Mar 1983612350
31 Dec 1879512310
30 Sep 1869110290
30 Jun 186869280
31 Mar 186448270
31 Dec 1760511260
30 Sep 1762111260
30 Jun 1765115250
31 Mar 1775618240
31 Dec 1679514240
30 Sep 1679813230
30 Jun 1676512220
31 Mar 1671114220
31 Dec 1565419262
30 Sep 1567027262
30 Jun 1564738262
31 Mar 1554836210
31 Dec 1442137222
30 Sep 1426629202
30 Jun 1414417192
31 Mar 149416202
31 Dec 131037150

Quality Earnings: 530317 has high quality earnings.

Growing Profit Margin: 530317's current net profit margins (4.7%) are higher than last year (2.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 530317's earnings have grown by 16.9% per year over the past 5 years.

Accelerating Growth: 530317's earnings growth over the past year (80.1%) exceeds its 5-year average (16.9% per year).

Earnings vs Industry: 530317 earnings growth over the past year (80.1%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: 530317's Return on Equity (15.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:45
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Godavari Drugs Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anil BurraFirstCall Research